ZeroHarm Sciences has raised $7.2M in seed funding, with Kotak Alternate Asset Managers and Alkemi Growth Capital backing the nano-technology supplements brand.
The company, which describes itself as India’s first nano-tech supplements player, sits at the intersection of advanced formulation science and preventive healthcare. Its pitch is precision: using nano-formulation strategies to boost bioavailability, so that time-tested Ayurvedic ingredients are absorbed and utilized more effectively by the body. ZeroHarm says it’s trusted by over 800,000 customers in India, with expansion underway into the U.S., U.K., and UAE. The round signals growing investor appetite for wellness brands that lean on evidence-aware positioning rather than quick-fix promises.


















